This study expands on our prior work with myc-rhGNS to establish a viable ERT treatment for MPS IIID; and provides further evidence that significant cellular disruptions in the brains of MPS IIID mice exist and that rhGNS corrects this pathology when delivered directly to the CNS in adult animals. This evidence concerns the gene MYC and mucopolysaccharidosis type 3D.